<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03884283</url>
  </required_header>
  <id_info>
    <org_study_id>CD0001</org_study_id>
    <nct_id>NCT03884283</nct_id>
  </id_info>
  <brief_title>Prospective, Multi-center Study to Assess Posterolateral Fusion Using FIBERGRAFT</brief_title>
  <official_title>A Post-market, Prospective, Multi-center, Nonrandomized Study to Assess Posterolateral Lumbar Fusions Using FIBERGRAFT BG Matrix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prosidyan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prosidyan, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, non-randomized (single arm), multi-center, post-market clinical study&#xD;
      designed to evaluate FIBERGRAFT® BG Matrix mixed with autograft and bone marrow aspirate in&#xD;
      up to 150 subjects with degenerative disc disease (DDD) with or without radiculopathy, or&#xD;
      spinal stenosis and/or spondylolisthesis requiring a fusion. The patient population will&#xD;
      include adult (skeletally mature) men and women undergoing 1 or 2 level fusion in the lumbar&#xD;
      spine (L2-S1) who are deemed eligible for the study, characterized by inclusion and exclusion&#xD;
      criteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 19, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spinal fusion</measure>
    <time_frame>12 months</time_frame>
    <description>Spinal fusion will be determined via radiographic imaging at 12 months.</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Spinal Stenosis Lumbar</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FIBERGRAFT BG Matrix</intervention_name>
    <description>Subjects who meet the criteria for entrance into the study will undergo posterolateral fusion using FIBERGRAFT® BG Matrix in combination with autograft and bone marrow aspirate (BMA)</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Informed Consent Form&#xD;
&#xD;
          2. Is at least 18 years of age and skeletally mature.&#xD;
&#xD;
          3. Must have symptomatic spinal stenosis and/or spondylolisthesis or degenerative disc&#xD;
             disease (DDD) at one or two adjacent levels from L2-S1, requiring a fusion.&#xD;
&#xD;
          4. Must have completed a minimum of three months of unsuccessful conservative,&#xD;
             non-operative care.&#xD;
&#xD;
          5. DDD and spinal stenosis and/or spondylolisthesis must be confirmed by MRI or CT scans.&#xD;
&#xD;
          6. Must score at least 40 points on the Oswestry Disability Index.&#xD;
&#xD;
          7. Must score at least a 4 on a 10 cm Visual Analog Scale for back or leg pain.&#xD;
&#xD;
          8. Must be able to comply with the protocol's follow-up schedule.&#xD;
&#xD;
          9. Must understand and sign the IRB approved informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptomatic at more than two levels.&#xD;
&#xD;
          2. Previous fusion surgery at any lumbar level with or without instrumentation (prior&#xD;
             discectomy, laminotomy, laminectomy or nucleolysis at the index level (&gt; 6 months) is&#xD;
             permitted).&#xD;
&#xD;
          3. Previous total disc replacement at any lumbar level.&#xD;
&#xD;
          4. Undergoing fusion for recurrent stenosis at the level to be treated.&#xD;
&#xD;
          5. Extraspinal cause of back and/or leg pain, or back and/or leg pain of unknown&#xD;
             etiology.&#xD;
&#xD;
          6. Spondylolisthesis not able to be reduced to grade I.&#xD;
&#xD;
          7. Lumbar scoliosis greater than 11 degrees.&#xD;
&#xD;
          8. Osteoporosis*, osteopenia, osteomalacia, Paget's disease, or metabolic or systemic&#xD;
             bone disorders that affect bone or wound healing.&#xD;
&#xD;
          9. Use of posterior instrumentation for stabilization is not possible.&#xD;
&#xD;
         10. Intra-operative soft tissue coverage is not possible.&#xD;
&#xD;
         11. Spinal tumors.&#xD;
&#xD;
         12. Active arachnoiditis.&#xD;
&#xD;
         13. Fractures of the epiphyseal plate or fractures for which stabilization of the fracture&#xD;
             is not possible.&#xD;
&#xD;
         14. Impaired calcium metabolism.&#xD;
&#xD;
         15. Active systemic infection or surgical site infection.&#xD;
&#xD;
         16. Osteomyelitis at the graft site.&#xD;
&#xD;
         17. Rheumatoid arthritis or other autoimmune disease.&#xD;
&#xD;
         18. Chronic steroid use (used steroids for one month within the last 6 months) or any&#xD;
             medical condition that requires treatment with drugs known to interfere with bone&#xD;
             healing.&#xD;
&#xD;
         19. Systemic disease such as AIDS, HIV, hepatitis (active), tuberculosis.&#xD;
&#xD;
         20. Morbid obesity defined as body mass index (BMI) &gt;40 or a weight more than 100 lbs over&#xD;
             ideal body weight.&#xD;
&#xD;
         21. Smokers unless the subject agrees to quit at least 2 weeks prior to and for the&#xD;
             duration of the study, confirmed by a carboxyhemoglobin test prior to surgery.&#xD;
&#xD;
         22. Psychosocial disorders that would preclude accurate evaluation or has a history of&#xD;
             recent substance abuse.&#xD;
&#xD;
         23. Active malignancy except non-melanoma skin cancer; history of any invasive malignancy&#xD;
             unless treated and in remission for at least five years.&#xD;
&#xD;
         24. Documented allergies to titanium.&#xD;
&#xD;
         25. Subjects with a history of anaphylaxis, history of multiple allergies, known allergies&#xD;
             to bovine collagen, or who are being treated for desensitization to meat products&#xD;
             because FIBERGRAFT® BG Matrix contains bovine collagen.&#xD;
&#xD;
         26. Pregnancy/able to become pregnant and not following a reliable contraceptive method,&#xD;
             or interested in becoming pregnant in the next two years.&#xD;
&#xD;
         27. Participation in another investigational study within 30 days.&#xD;
&#xD;
         28. Prisoners.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Long Beach Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Orthopaedic Surgical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Neurosurgery</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Institute of Western Kentucky</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Spine &amp; Scoliosis Institute at OrthoBethesda</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health Orthopaedic Institute</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KeiperSpine, PC</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopedic and Neurologic Research Institute</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Orthopaedics</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 19, 2019</study_first_submitted>
  <study_first_submitted_qc>March 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2019</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

